Characterized by a rapidly increasing prevalence, elevated mortality and rehospitalization
rates, and inadequacy of pharmaceutical therapies, heart failure with preserved ejection …

Heart failure with preserved ejection fraction (HFpEF) is a syndrome with an unfavorable
prognosis, and the number of the patients continues to grow. Because there is no effective …

Aims Attenuating exercise‐induced elevated left atrial pressure with an atrial shunt device is
under clinical investigation for treatment of symptomatic heart failure (HF). Methods and …

Methods and Results: AFR-PRELIEVE is a prospective, non-randomized, open-label, multi-
center study in patients with symptomatic heart failure NYHA class III or IV and pulmonary …

Heart failure with preserved ejection fraction (HFpEF) is a major challenge in cardiovascular
medicine, accounting for≈ 50% of all cases of heart failure. Despite the ongoing efforts, no …

Objectives A novel Occlutech atrial flow regulator (AFR) implantation gives an atrial septal
predefined predictable fenestration. Background Atrial septostomy relieves syncope in …

Heart failure with preserved ejection fraction (HFpEF) accounts for more than half of heart
failure hospital admissions in the last years and is burdened by high mortality and poor …

Despite ongoing advances in the treatment of heart failure, overall symptom burden remains
high. Underlying the primary symptom of dyspnea are often elevations in left atrial …

Abstract Purpose of the Review Targeted pharmacotherapies did improve survival rates,
exercise capacity, and quality of life (QoL) of PAH patients. However, these pharmacological …

A novel pump, the left atrial assist device (LAAD), is a device specifically for the treatment of
heart failure with preserved ejection fraction (HFpEF). The LAAD is a mixed-flow pump that …